Source: British journal of pharmacology. Unidade: FM
Subjects: RECOMBINAÇÃO GENÉTICA, ADENOSINA, INIBIDORES DE ENZIMAS, REPARAÇÃO DE DNA, TRAUMATISMOS CEREBRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERGER, Nathan A. e SORIANO, Francisco Garcia. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. British journal of pharmacology, v. 175, n. 2, p. 192-222, 2018Tradução . . Disponível em: https://doi.org/10.1111/bph.13748. Acesso em: 02 nov. 2024.APA
Berger, N. A., & Soriano, F. G. (2018). Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. British journal of pharmacology, 175( 2), 192-222. doi:10.1111/bph.13748NLM
Berger NA, Soriano FG. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases [Internet]. British journal of pharmacology. 2018 ; 175( 2): 192-222.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1111/bph.13748Vancouver
Berger NA, Soriano FG. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases [Internet]. British journal of pharmacology. 2018 ; 175( 2): 192-222.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1111/bph.13748
